Latest Regulatory Process News

Green Technology Metals has extended its Letter of Interest with Export Development Canada for up to C$100 million in financing, reinforcing the strategic development of its Seymour Lithium Project in Ontario.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.

Robex Resources shareholders have overwhelmingly approved a merger with Predictive Discovery Limited, setting the stage for a combined entity targeting over 400,000 ounces of gold production annually by 2029.

BCI Minerals has secured crucial environmental approvals to proceed with its optimized dredging strategy at the Mardie Salt Operation, setting the stage for first salt shipments by late 2026.

Sarytogan Graphite Limited updates investors on its $5 million capital raising, highlighting regulatory approval delays but confirming near-term funding to advance its key graphite project.

Ariana Resources reports encouraging progress in its Dokwe Gold Project drilling campaign, highlighting geological confirmations and plans to extend exploration for potential resource growth.

Activeport Group Ltd has revised the timetable for its pro-rata bonus issue of unquoted options, outlining key dates and eligible shareholders across multiple countries.

Invictus Energy updates progress on its AMOG joint venture with Al Mansour Holdings, revealing ongoing negotiations for a significant Qatari ownership stake and deferral of a key placement settlement.

Reef Casino Trust’s takeover bid by Iris Cairns Property faces a regulatory hurdle as Queensland’s Office of Liquor and Gaming Regulation delays suitability investigations, pushing the offer period beyond March 2026.

WA1 Resources has secured Major Project Status for its Luni Niobium Project, marking it as a critical national asset with government-backed facilitation for three years.

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

Elsight’s Halo platform has advanced to the final phase of a major U.S. Defense Innovation Unit challenge, securing significant funding and positioning the company at the forefront of a generational unmanned systems investment cycle.